Ketorolac is limited to five days because it carries significantly higher risks of gastrointestinal bleeding, kidney injury, and surgical bleeding than other NSAIDs, and those risks climb sharply with each additional day of use. The five-day cap, set by the FDA, reflects the point at which the drug’s powerful pain relief no longer outweighs the accumulating danger to your stomach lining, kidneys, and blood clotting ability.
Ketorolac Hits COX-1 Harder Than Any Other NSAID
All NSAIDs work by blocking enzymes called COX-1 and COX-2. COX-2 is the one responsible for pain and inflammation, which is the target you want. COX-1, on the other hand, does useful housekeeping: it helps maintain the protective mucus lining of your stomach and supports normal blood flow to your kidneys.
Ketorolac is the most COX-1-selective NSAID ever tested in a full laboratory comparison, published in the Proceedings of the National Academy of Sciences. That COX-1 selectivity is what makes it such an effective painkiller, often compared to low-dose opioids for acute post-surgical pain. But it’s also what makes it so dangerous over time. The protective lining of your stomach and intestines depends on COX-1, and ketorolac suppresses it more aggressively than ibuprofen, naproxen, or diclofenac.
The GI Bleeding Risk Is Roughly 5 Times Higher
The gap between ketorolac and other common painkillers is not subtle. In comparative data on upper gastrointestinal bleeding, ketorolac carries a relative risk of about 14.5 compared to people not taking any NSAID. For context, ibuprofen’s relative risk is 2.7, naproxen’s is 5.6, and diclofenac’s is 4.0. That makes ketorolac roughly five times more likely to cause serious GI complications than a typical NSAID, and more than five times riskier than ibuprofen specifically.
This is not a small statistical difference. It means that every day you continue taking ketorolac, you are exposing an increasingly vulnerable stomach lining to a drug that strips away its defenses faster than any alternative. After five days, the accumulated suppression of that protective mucus layer reaches a point where the likelihood of ulceration or bleeding becomes unacceptable for a pain management drug.
Kidney Damage Rises With Duration
Your kidneys rely on a steady blood supply that COX-1 helps regulate. When ketorolac suppresses that process, blood flow to the kidneys drops. In someone with healthy kidneys taking the drug for fewer than five days, this typically does not cause lasting harm. The kidneys recover once the drug clears your system.
Beyond five days, the risk of acute kidney injury increases. The sustained reduction in renal blood flow can push kidneys past their ability to compensate, particularly in people who are dehydrated, older, or taking other medications that affect kidney function. The five-day limit exists in part because clinical data shows the drug is not associated with increased kidney injury risk when used within that window in patients with normal renal function, but the safety margin disappears rapidly after that.
It Impairs Blood Clotting the Entire Time You Take It
Ketorolac inhibits platelet function, which means your blood doesn’t clot as effectively while you’re on it. This is a particular concern in the post-surgical setting where ketorolac is most commonly used. Post-operative hematomas and wound bleeding have been reported with its use, and the FDA label specifically warns that it should be used with caution when hemostasis (the body’s ability to stop bleeding) is critical.
The good news is that this effect is reversible. Platelet function returns to normal within 24 to 48 hours after stopping the drug. But the longer you take ketorolac, the longer you’re operating with impaired clotting, and the greater the chance of a bleeding complication, whether at a surgical site or in the GI tract. The five-day window limits that exposure to the acute recovery period when strong pain control is most needed.
How the Five Days Are Counted
Ketorolac is often started as an injection (IV or intramuscular) in a hospital or emergency department, then switched to oral tablets once you’re able to take pills. The five-day limit covers the total combined duration of both forms. If you received two days of injections in the hospital and then went home with oral ketorolac, you have three more days of tablets, not five.
In Canada, the rules are even stricter. Health Canada limits the injectable form to a maximum of two days, with the total combined IV/IM and oral treatment still capped at five days. This reflects the same safety concerns, with an added layer of caution around the higher blood levels achieved through injection.
Some People Should Use It for Even Less Time
The five-day maximum assumes a relatively healthy adult. For several groups, ketorolac is either contraindicated entirely or carries enough additional risk that shorter courses or lower doses are standard. These include people with moderate to severe kidney impairment, active GI ulcers or inflammatory bowel disease, bleeding disorders or a high risk of hemorrhage, severe liver disease, and uncontrolled heart failure. The drug is also contraindicated in the period around coronary artery bypass surgery, during the third trimester of pregnancy, and in patients under 18.
Older adults face compounded risk because kidney function naturally declines with age, stomach lining becomes more fragile, and many are on blood thinners or other medications that interact with ketorolac. The drug also cannot be combined with other NSAIDs, so you shouldn’t be taking ibuprofen or naproxen alongside it.
Why Not Just Use a Lower Dose for Longer?
This is a reasonable question, but ketorolac’s extreme COX-1 selectivity means even reduced doses continue to hammer the stomach lining and suppress kidney blood flow disproportionately compared to alternatives. At a dose low enough to be safe for extended use, it would not offer meaningful advantages over ibuprofen or naproxen, which are approved for long-term use at appropriate doses. Ketorolac’s entire clinical value lies in its short-term potency for acute pain, particularly after surgery or in emergency settings. Once the acute pain window passes, switching to a less aggressive NSAID or a different class of painkiller is both safer and equally effective for ongoing pain management.